利奈唑胺联合抗结核药对耐多药肺结核患者痰菌转阴及病灶吸收情况的影响  

Effect of Linezolid Combined with Antitubercular Agent on Sputum Negative and Absorption of Lesions in Patients with Multidrug-resistant Pulmonary Tuberculosis

作　　者：邓群[1] 王彩纹[1] 刘建锋[1] DENG Qun;WANG Caiwen;LIU Jianfeng(Jiangxi Chest Hospital,Nanchang Jiangxi 330006,China)

机构地区：[1]江西省胸科医院,江西南昌330006

出　　处：《药品评价》2022年第5期287-289,共3页Drug Evaluation

摘　　要：目的:探讨利奈唑胺联合抗结核药在耐多药肺结核(MDR-TB)患者中的效果。方法:选取2018年7月至2020年7月江西省胸科医院收治的60例MDR-TB患者,按随机数字表法分为对照组(30例),观察组(30例)。对照组予以常规抗结核药,观察组加用利奈唑胺,两组连续用药6个月。对比两组炎性因子水平、痰菌转阴率、病灶吸收情况、不良反应。结果:治疗前,两组白介素-1(IL-1)、肿瘤坏死因子-α(TNF-α)、白介素-6(IL-6)相比,差异无统计学意义(P>0.05);治疗6个月后,观察组IL-1、TNF-α、IL-6低于对照组,差异有统计学意义(P<0.01);观察组治疗1个月、3个月、6个月的痰菌转阴率高于对照组,治疗6个月后的病灶吸收总有效率高于对照组,均差异有统计学意义(均P<0.05);两组不良反应差异无统计学意义(P>0.05)。结论:利奈唑胺联合抗结核药能够明显降低MDR-TB患者炎性因子水平,提高痰菌转阴与病灶吸收率,且无严重不良反应,安全可行。Objective:To investigate the effect of linezolid combined with antitubercular agent in patients with multidrugresistant tuberculosis(MDR-TB).Methods:A total of 60 MDR-TB patients admitted to Jiangxi Chest Hospital from July 2018 to July 2020 were selected and divided into a control group(30 cases)and an observation group(30 cases)according to the random number table method.The control group was given conventional antitubercular agent,and the observation group was given linezolid on the basis of the control group.Both groups treated continuously for 6 months.The levels of inflammatory factors,sputum bacteria conversion rate,lesion absorption,and adverse reactions were compared between the two groups.Results:Before treatment,there was no statistically significant difference between the two groups of interleukin-1(IL-1),tumor necrosis factor-α(TNF-α),and interleukin-6(IL-6)(P>0.05);after treatment for 6 months,the levels of IL-1,TNF-α,and IL-6 in the observation group were lower than those in the control group,the difference was statistically significant(P<0.01);the observation group had a higher rate of negative conversion of sputum bacteria during 1,3,and 6 months of treatment and the effective rate of focal absorption after 6 months of treatment was higher than that of the control group,the difference was statistically significant(P<0.05);the adverse reactions of the two groups were similar,and the difference was not statistically significant(P>0.05).Conclusion:Linezolid combined with antitubercular agent can significantly reduce the level of inflammatory factors in patients with MDR-TB,improve the rate of sputum conversion and focal absorption without serious adverse reactions,and is safe and feasible.

关 键 词：广泛耐药结核 抗结核药 利奈唑胺 痰菌转阴 不良反应 

分 类 号：R521[医药卫生—内科学]